Stemedica Granted US Patent for Cellular Scaffold
Thursday, February 16, 2012
Multi-stem cell products address need in the $12.5 billion wound care field.
Current Status and Future Development of Cell Transplantation Therapy for Periodontal Tissue Regeneration
Thursday, February 16, 2012
This paper reviews the current research targeting cell-based therapies for periodontal regeneration and then discusses the risks and governmental controls of stem cell transplantation therapy.
Plasticell Announces Grant of Fundamental CombiCult™ Patents in USA and Japan
Tuesday, February 14, 2012
Patents have now been issued in Europe, USA, Japan, Australia and Singapore.
The Gamida Cell-Teva Joint Venture Concludes Enrollment for the Phase III Study of StemEx(R)
Tuesday, February 14, 2012
The results of the StemEx study, a cord blood stem cell product for leaukemia and lymphoma, are expected during the second half of 2012.
Cytomedix Expands Commitment to Regenerative Medicine with Acquisition of Aldegen
Monday, February 13, 2012
Under the terms of the transaction as described below, Cytomedix issued preferred shares valued at $16 million based on a 10-day volume-weighted average price calculated through February 2, 2012.
Roche’s xCELLigence Cardio Instrument Used to Study Stem Cell-Derived Cardiomyocytes
Monday, February 13, 2012
Instrument detected beating rhythm and proarrhythmic effects of nine different compounds on a monolayer of cells, providing evidence for the potential of future screening assays.
American CryoStem Joins Alliance for Regenerative Medicine
Thursday, February 09, 2012
The company’s decision to join ARM was based on the alignment of its ongoing mission to offer the highest quality products and services to help accelerate the regenerative medicine industry and ARM's support of policy efforts toward safe and reliable cellular products.
VistaGen Increases Its Drug Rescue Opportunities
Thursday, February 09, 2012
Long-term relationship with global contract research and development organization expands to include right-of-first-offer for potential drug rescue candidates.
Prometheus Signs Research & Collaboration Agreement with Worldwide Pharmaceutical Company
Wednesday, February 08, 2012
The collaboration will use Prometheus' proprietary oncology diagnostic platform (CEER) to develop diagnostic arrays relating to the partner's oncology pipeline.
|
|
|
| << | 1 2 3 4 5 6 7 | >> | | Showing Results 1 - 10 of 1394 |
|
|
